KPTI vs ROST · rev $68.5M vs P/E 21, rev $22.75B
Karyopharm Therapeutics Inc (KPTI) versus Ross Stores Inc (ROST) — a side-by-side from cached financials, not a winner call.
Karyopharm Therapeutics Inc (KPTI) is a biotechnology company listed on US.
Ross Stores Inc (ROST) is a apparel retail company listed on US.
Latest reported KPTI revenue for 2026-06-30 was $68.5M. Net income was -$89.4M. Revenue was up 95.3% from 2026-03-31 to 2026-06-30. KPTI currently screens at market cap $205.6M.
Latest reported ROST revenue for 2026-01-31 was $22.75B. Net income was $2.15B. Revenue was up 7.7% from 2025-02-01 to 2026-01-31. ROST currently screens at market cap $43.03B and trailing P/E 20.8.
KPTI currently screens at market cap $205.6M. ROST currently screens at market cap $43.03B and trailing P/E 20.8.
Not investment advice. Open the KPTI and ROST stock pages for the full models.
Not investment advice.